Skip to content
value.today
AP Pharma Inc /de/ logo

AP Pharma Inc /de/

AP Pharma Inc /de/ is listed today as Heron Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of AP Pharma Inc /de/
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2023$30 MPrivate placement after listing$10 to $50 million

AP Pharma Inc /de/: Private sale, Jul 2023

Investors in this round

7 investors had bought by the notice of Aug 1, 2023: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Craig Collard · Executive Officer, Director
  • Ira Duarte · Executive Officer
  • Adam Morgan · Director
  • Christian Waage · Director
  • Craig Johnson · Director
  • Kevin Kotler · Director
  • Sharmila Dissanaike · Director
  • Susan Rodriguez · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ira Duarte, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 1, 2023. Read the notice at the SEC.

equity, optionsSEC
Jul 2012$54 MPrivate placement after listing$50 to $250 million

AP Pharma Inc /de/: Private sale, Jul 2012

Investors in this round

21 investors had bought by the notice of Aug 10, 2012: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$54 M of $54 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,613,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John B. Whelan · Executive Officer, Director
  • Michael A. Adam · Executive Officer
  • Thomas A. Ottoboni · Executive Officer
  • Barry D. Quart · Director
  • Kevin C. Tang · Director
  • Robert R. Rosen · Director
  • Stephen R. Davis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • JEFFERIES & COMPANY, INC. (CRD 2347) · New York, New YorkSold in CA, MA, MD, NY, TX, and outside the US

Signed by John B. Whelan, Chief executive officer. Source: SEC Form D, newest notice filed Aug 10, 2012. Read the notice at the SEC.

equitySEC
Jul 2011$24 MA long-registered or listed company$10 to $50 million

AP Pharma Inc /de/: Private sale, Jul 2011

Investors in this round

22 investors had bought by the notice of Jul 11, 2011: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$24 M of $24 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,170,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John A. Barr · Executive Officer
  • John B. Whelan · Executive Officer, Director
  • Michael A. Adam · Executive Officer
  • Gregory C. Turnbull · Director
  • Kevin C. Tang · Director
  • Paul A. Goddard · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MTS SECURITIES, LLC (CRD 104059) · New York, New YorkSold in CA, CT, MA, NJ, NY

Signed by John B. Whelan, Chief executive officer. Source: SEC Form D, newest notice filed Jul 11, 2011. Read the notice at the SEC.

equity, optionsSEC
Oct 2009$8 MA long-registered or listed company$2 to $10 million

AP Pharma Inc /de/: Private sale, Oct 2009

Investors in this round

7 investors had bought by the notice of Nov 5, 2009: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $17 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: (i) Common Stock and (ii) Warrants to purchase shares of Common Stock (including the shares of Common Stock issuable upon exercise of the Warrants).
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Barr · Executive Officer · SVP, Research and Development
  • John Whelan · Executive Officer · VP Finance and Chief Financial Officer
  • Ronald Prentki · Executive Officer, Director · President and Chief Executive Officer
  • Gregory Turnbull · Director
  • Kevin Tang · Director
  • Paul Goddard · Director
  • Robert Zerbe · Director
  • Toby Rosenblatt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Whelan, VP Finance and Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 5, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Heron Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: CINVANTI $96.76 million (62%), ZYNRELEF $38.07 million (25%), APONVIE $11.57 million (7%), SUSTOL $8.50 million (5%).

    Annual report (SEC XBRL) · Dec 2025

  • AP Pharma Inc /de/ chose not to state its revenue in its newest notice of a funding round (Aug 2023).

    SEC Form D · Aug 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2023

Products and services#

No products or services of AP Pharma Inc /de/ are on record.

Investors#

No investor of AP Pharma Inc /de/ is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Heron Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by AP Pharma Inc /de/
NameRoleNamed in
Craig CollardExecutive officerAug 2023
Ira DuarteExecutive officerAug 2023
John B. WhelanExecutive officerAug 2012
Michael A. AdamExecutive officerAug 2012
Thomas A. OttoboniExecutive officerAug 2012
John A. BarrExecutive officerJul 2011
John BarrSVP, Research and DevelopmentNov 2009
John WhelanVP Finance and Chief Financial OfficerNov 2009
Ronald PrentkiPresident and Chief Executive OfficerNov 2009
Adam MorganDirectorAug 2023
Christian WaageDirectorAug 2023
Craig CollardDirectorAug 2023
Craig JohnsonDirectorAug 2023
Kevin KotlerDirectorAug 2023
Sharmila DissanaikeDirectorAug 2023
Susan RodriguezDirectorAug 2023
Barry D. QuartDirectorAug 2012
John B. WhelanDirectorAug 2012
Kevin C. TangDirectorAug 2012
Robert R. RosenDirectorAug 2012
Stephen R. DavisDirectorAug 2012
Gregory C. TurnbullDirectorJul 2011
Paul A. GoddardDirectorJul 2011
Gregory TurnbullDirectorNov 2009
Kevin TangDirectorNov 2009
Paul GoddardDirectorNov 2009
Robert ZerbeDirectorNov 2009
Ronald PrentkiPresident and Chief Executive OfficerNov 2009
Toby RosenblattDirectorNov 2009

Went public since 2011. Its SEC number is that of a company listed on a stock exchange.